

Santen Completes Construction Work on North Building of its Nara Research and Development Center

Osaka, Japan, November 22, 2002 --- Santen Pharmaceutical Co., Ltd. has announced that construction work on the North Building of its Nara Research and Development Center will be completed on Monday, November 25, 2002.

The Nara Research and Development Center was established in April 1996 to conduct discovery and development research to create pharmaceuticals that contribute to the treatment of ophthalmic disorders.

The expansion of the Center enables Santen to further reinforce ophthalmic research. Santen will also transfer some functions of the Central Research Laboratories in Osaka, including rheumatic research, synthetic and safety research and research support, to the Nara Research and Development Center. As a result, ophthalmic research and rheumatic research will be integrated. The number of staff in the Center will be doubled to approximately 220.

Santen specializes in the research, development, manufacturing and marketing of ophthalmic and anti-rheumatic pharmaceuticals to protect and improve eyesight and health. Santen has created innovative pharmaceuticals for all types of ophthalmic disorders and provides information tailored to clinical needs. As a result, Santen leads Japan's market for prescription ophthalmics, which account for nearly 80 percent of the Company's sales.

Overview of the Nara Research and Development Center

Address: 8916-16, Takayama-cho, Ikoma-shi, Nara, Japan
Lot area: 36,000 square meters
Total floor space: North Building: Approximately 10,000 square meters
(five stories above ground and one below)
Total: Approximately 20,000 square meters

Image of the Nara Research and Development Center

(The newly constructed North Building is on the left.)



Note: The above image can be downloaded from Santen's Web site.

(URL: <http://www.santen.co.jp/ir/en/news/picture/20021122.jpg>)